Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, the maximum tolerated dose and the
recommended dose for phase II studies of a chemotherapy-combination of sorafenib, irinotecan,
and 5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) as first-line treatment for metastatic
colorectal cancer.